ClinicalTrials.gg
CompletedNCT01689740Updated Jun 6, 2025Results posted

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

A Phase 2 interventional study of Active Placebo Dose MDMA-assisted therapy (25 mg) and Full Dose MDMA-assisted therapy (125 mg) in Posttraumatic Stress Disorder (PTSD), sponsored by Lykos Therapeutics. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
28th of 38
10 · median 25
Started
2013
with 1 other
Phase 2
28 of 38
10 open now
Registered
6th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 28th largest by enrollment, is one of 2 that started in 2013, is one of 28 in phase 2, and was the 6th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.

The main question it aims to answer is: Is there a reduction in PTSD symptoms in people given a low dose of MDMA with therapy versus a high dose of MDMA with therapy?

Researchers will compare two sessions of MDMA-assisted therapy with either 25 mg of MDMA HCl or 125 mg of MDMA HCl in Stage 1.

Participants will undergo preparatory therapy sessions without any study drug, followed by two sessions of MDMA-assisted therapy, each followed by integrative therapy sessions without study drug. Participants who received 25 mg during Stage 1 will be given the option to enroll in Stage 2 and complete two additional open-label MDMA-assisted therapy sessions with the full dose of 125 mg MDMA.

Read the detailed description

This randomized, double-blind, active placebo-controlled Phase 2 pilot study investigated the safety and efficacy of MDMA-assisted psychotherapy in 10 people with chronic, treatment-resistant posttraumatic stress disorder (PTSD), comparing the effects of low and full dose MDMA as an adjunct to psychotherapy. The first two subjects were enrolled in the open label full dose lead-in with 125 mg of midomafetamine HCl, followed by a supplemental half-dose of 62.5 mg after 1.5 to 2.5 hours. The remaining eight subjects enrolled in Stage 1 of the study and received either an active placebo dose (low dose of 25 mg midomafetamine HCl with a supplemental half-dose of 12.5 mg) or a fully active dose (125 mg midomafetamine HCl with a supplemental half-dose of 62.5 mg) during two experimental psychotherapy session, each lasting six to eight hours and scheduled three to five weeks apart.

Upon enrollment, subjects met with their therapist team for three preparatory sessions. After each MDMA-assisted psychotherapy session, subjects met with their therapist team for integrative psychotherapy sessions.

The extent of PTSD symptoms was assessed at baseline and two months after the second experimental session using the Clinician Administered PTSD Scale (CAPS) (Blake et al., 1995). Safety measures, vital signs, and a measurement of psychological distress was assessed during all experimental sessions. Blood pressure and heart rate were assessed periodically during each experimental session.

Subjects who enrolled in Stage 1 and received the active placebo had the opportunity to enroll in Stage 2 of the study and complete open-label experimental sessions with the fully active dose of midomafetamine HCl (125 mg and 62.5 mg supplemental) on the same schedule as Stage 1.

03

Conditions studied

  • Posttraumatic Stress Disorder (PTSD)

Keywords

  • MDMA
  • Posttraumatic stress disorder
  • PTSD
  • Israel
  • psychotherapy
  • midomafetamine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic PTSD with a duration of 6 months or longer.
  • Have a CAPS score showing moderate to severe symptoms.
  • Had at least one unsuccessful attempt at treatment for PTSD, either with talk therapy or with drugs, or stopped treatment because of inability to tolerate psychotherapy or drug therapy.
  • Are at least 18 years old.
  • Generally healthy.
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors.
  • Are willing to refrain from taking any psychiatric medications during the study period.
  • Agree that, one week before the MDMA session, will refrain from taking all below unless with prior approval of research team: herbal supplements, nonprescription medications (with the exception of nonsteroidal anti-inflammatory drugs or acetaminophen, any prescription medications, with the exception of pills, thyroid hormone, or other medications;
  • Are willing to follow restrictions and guidelines concerning consumption of food, beverages. and nicotine the night before and just prior to each experimental session.
  • Are willing to remain overnight at the study site.
  • Are willing to be contacted via telephone for all necessary telephone contacts.
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control.
  • Agree not to participate in any other clinical trial for the duration of this clinical trial, including the follow-up period.
  • Are proficient in speaking and reading Hebrew.
  • Agree to have all psychotherapy sessions recorded to audio/video.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if they can have children and are not practicing an effective means of .
  • Weigh less than 48 kg.
  • Are abusing illegal drugs.
  • Have used "Ecstasy" (material represented as containing MDMA) more than five times or at least once within 6 months of the MDMA session.
  • Are unable to give adequate .
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary.
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Lead in: 125 mg MDMA-assisted therapy (Open-Label)

    Participants receive open-label MDMA with an initial dose of 125 mg midomafetamine HCl, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.

    Drug: Open-Label Full Dose MDMA-assisted therapy (125 mg) · Behavioral: Psychotherapy

  • Placebo comparator
    Active placebo dose MDMA-assisted therapy (25 mg)

    Participants receive initial dose of 25 mg midomafetamine HCl, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.

    Drug: Active Placebo Dose MDMA-assisted therapy (25 mg) · Behavioral: Psychotherapy

  • Experimental
    Full dose MDMA-assisted therapy (125 mg)

    Participants receive initial dose of 125 mg midomafetamine HCl, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.

    Drug: Full Dose MDMA-assisted therapy (125 mg) · Behavioral: Psychotherapy

Interventions

  • DrugActive Placebo Dose MDMA-assisted therapy (25 mg)

    Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl

  • Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl

  • Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA, midomafetamine HCl

  • BehavioralPsychotherapy

    Non-directive psychotherapy will be conducted throughout the study.

    Also known as: Manualized MDMA-assisted psychotherapy

06

What researchers measure

Primary outcomes

  1. Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)

Secondary outcomes

  1. Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to End of Stage 2

  2. Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to 12 months post-final experimental session

  3. Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1

    Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

    Time frame: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)

  4. Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2

    Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

    Time frame: Baseline to End of Stage 2

  5. Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up

    Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

    Time frame: Baseline to 12 month post-final experimental session

  6. Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 1

    The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

    Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)

  7. Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 2

    The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

    Time frame: Baseline to End of Stage 2

  8. Change in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up

    The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

    Time frame: Baseline to 12 months post-final experimental session

  9. Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1

    The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

    Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)

  10. Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2

    The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

    Time frame: Baseline to End of Stage 2

  11. Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up

    The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

    Time frame: Baseline to 12 months post-final experimental session

  12. Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)

  13. Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline to End of Stage 2

  14. Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline to 12 months post-final experimental session

07

Results

Posted Oct 30, 2020

Participant flow

Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, through the Israeli Defense Forces (IDF) and through word of mouth.

Stage 1
Participant flow — Stage 1
MilestoneOpen-Label: 125 mg MDMA-assisted TherapyBlinded: Full Dose MDMA-assisted TherapyBlinded: Active Placebo Dose MDMA-assisted Therapy
Started253
Completed253
Not completed000
Stage 2
Participant flow — Stage 2
MilestoneOpen-Label: 125 mg MDMA-assisted TherapyBlinded: Full Dose MDMA-assisted TherapyBlinded: Active Placebo Dose MDMA-assisted Therapy
Started002
Completed002
Not completed000
12 Month Follow-Up
Participant flow — 12 Month Follow-Up
MilestoneOpen-Label: 125 mg MDMA-assisted TherapyBlinded: Full Dose MDMA-assisted TherapyBlinded: Active Placebo Dose MDMA-assisted Therapy
Started253
Completed252
Not completed001

Outcome measures

PrimaryChange in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
Reported as:
Mean · score on a scale
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 1-42.0 ± 9.90-9.0 ± 15.62-34.6 ± 16.29
SecondaryChange in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to End of Stage 2
Reported as:
Mean · score on a scale
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2
score on a scaleStage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to End of Stage 2-23.0 ± 15.56
SecondaryChange in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to 12 months post-final experimental session
Reported as:
Mean · score on a scale
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Clinical Administered PTSD Scale (CAPS-IV) Total Score From Baseline to Long-Term Follow-Up-39.0 ± 14.14-34.5 ± 20.51-48.8 ± 20.39
SecondaryChange in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1

Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

Time frame:
Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to End of Stage 1-17.0 ± 2.830.3 ± 4.73-17.0 ± 12.59
SecondaryChange in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2

Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

Time frame:
Baseline to End of Stage 2
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2
score on a scaleStage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy
Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to End of Stage 2-6.5 ± 4.95
SecondaryChange in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up

Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.

Time frame:
Baseline to 12 month post-final experimental session
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Beck Depression Inventory (BDI-II) Total Scores From Baseline to Long-Term Follow-Up-17.0 ± 5.66-3.5 ± 4.95-18.4 ± 11.10
SecondaryChange in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 1

The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

Time frame:
Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 1
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 115.0 ± 21.21-2.3 ± 8.7418.2 ± 11.14
SecondaryChange in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 2

The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

Time frame:
Baseline to End of Stage 2
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 2
score on a scaleStage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy
Change in Global Assessment of Functioning (GAF) Scale From Baseline to End of Stage 28.0 ± 9.90
SecondaryChange in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up

The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

Time frame:
Baseline to 12 months post-final experimental session
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Global Assessment of Functioning (GAF) Scale From Baseline to Long-Term Follow-Up5 ± 7.07-1.5 ± 0.7126.6 ± 10.33
SecondaryChange in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1

The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

Time frame:
Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Reported as:
Mean · score on a scale
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 1-19.0 ± 5.661.3 ± 13.43-17.4 ± 9.91
SecondaryChange in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2

The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

Time frame:
Baseline to End of Stage 2
Reported as:
Mean · score on a scale
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2
score on a scaleStage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to End of Stage 2-11.5 ± 10.61
SecondaryChange in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up

The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms.

Time frame:
Baseline to 12 months post-final experimental session
Reported as:
Mean · score on a scale
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Posttraumatic Stress Diagnostic Scale (PDS) Symptom Severity Score From Baseline to Long-Term Follow-Up-23.0 ± 0-10 ± 9.90-20.4 ± 12.70
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1

The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 1-7.5 ± 6.361.0 ± 5.29-1.8 ± 4.44
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2

The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline to End of Stage 2
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2
score on a scaleStage 2 Open-Label Crossover 125 mg MDMA-assisted Therapy
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to End of Stage 2-3.5 ± 3.54
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up

The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline to 12 months post-final experimental session
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up
score on a scaleLead in: 125 mg MDMA (Open Label) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyFull Dose MDMA (125 mg) and Psychotherapy
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to Long-Term Follow-Up-3.5 ± 3.54-2.0 ± 4.24-2.2 ± 5.40

Adverse events

Collected over From baseline to study completion (approximately 18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lead In Open-Label: 125 mg MDMA-assisted Therapy0/2 (0%)0/2 (0%)2/2 (100%)
Blinded Full Dose MDMA-assisted Therapy (125 mg) (Stage 1)0/5 (0%)0/5 (0%)4/5 (80%)
Blinded Active Placebo MDMA-assisted Therapy (Stage 1)0/3 (0%)0/3 (0%)1/3 (33.3%)
Open-Label Full Dose MDMA-assisted Therapy (125 mg) (Stage 2)0/2 (0%)0/2 (0%)2/2 (100%)
12 Month Follow-Up: Open-Label Full Dose Lead-In0/2 (0%)0/2 (0%)0/2 (0%)
12 Month Follow-Up: Blinded Full Dose0/5 (0%)0/5 (0%)1/5 (20%)
12 Month Follow-Up: Active Placebo Dose0/2 (0%)0/2 (0%)0/3 (0%)
SRRs: Full Dose0/5 (0%)0/5 (0%)5/5 (100%)
SRRs: Active Placebo0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventLead In Open-Label: 125 mg MDMA-assisted TherapyBlinded Full Dose MDMA-assisted Therapy (125 mg) (Stage 1)Blinded Active Placebo MDMA-assisted Therapy (Stage 1)Open-Label Full Dose MDMA-assisted Therapy (125 mg) (Stage 2)12 Month Follow-Up: Open-Label Full Dose Lead-In12 Month Follow-Up: Blinded Full Dose12 Month Follow-Up: Active Placebo DoseSRRs: Full DoseSRRs: Active Placebo
AnxietyPsychiatric disorders1/24/50/30/20/20/50/35/51/3
InsomniaPsychiatric disorders1/20/50/30/20/20/50/35/51/3
FatigueGeneral disorders0/20/50/30/20/20/50/35/52/3
HeadacheNervous system disorders0/21/50/30/20/20/50/34/50/3
Low moodGeneral disorders0/20/50/30/20/20/50/33/52/3
Muscle tensionGeneral disorders0/20/50/30/20/20/50/32/52/3
RestlessnessGeneral disorders0/20/50/30/20/20/50/33/52/3
Need more sleepGeneral disorders0/20/50/30/20/20/50/33/51/3
PyrexiaGeneral disorders1/21/50/30/20/20/50/30/50/3
AsthmaRespiratory, thoracic and mediastinal disorders1/20/50/30/20/20/50/30/50/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lead in: 125 mg MDMA (Open Label) and PsychotherapyFull Dose MDMA (125 mg) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyTotal
Mean40.5 ± 19.7235.1 ± 10.2138.5 ± 8.6837.2 ± 10.57
Sex: Female, Male
Sex: Female, Male(Participants)Lead in: 125 mg MDMA (Open Label) and PsychotherapyFull Dose MDMA (125 mg) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyTotal
Female1304
Male1236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lead in: 125 mg MDMA (Open Label) and PsychotherapyFull Dose MDMA (125 mg) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyTotal
Hispanic or Latino0000
Not Hispanic or Latino25310
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lead in: 125 mg MDMA (Open Label) and PsychotherapyFull Dose MDMA (125 mg) and PsychotherapyActive Placebo Dose MDMA (25 mg) and PsychotherapyTotal
Ethnicity — White/Caucasian2529
Ethnicity — Other0011
08

Study locations

1 site
  • Beer Yaakov Hospital
    Be'er Ya'aqov, 70350, Israel
09

References and documents

Publications

  • Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995 Jan;8(1):75-90. doi: 10.1007/BF02105408. PubMed 7712061 ↗
  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Apr 2016, 38 months.

Results were first posted in Oct 2020, 4 years 6 months after primary completion. A results delay was requested in Aug 2018.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 38 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 21, 2012
StartActual
Jan 17, 2013
Primary completionActual
Apr 7, 2016
CompletionActual
Jul 16, 2017
Results delay requested
Aug 15, 2018
Results first posted
Oct 30, 2020
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01689740
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Jan 17, 2013
Primary completion
Apr 7, 2016
Completion
Jul 16, 2017
Results posted
Oct 30, 2020
Last update
Jun 6, 2025

Study contacts

Moshe Kotler
principal investigator · Beer Yaakov Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion